RT Journal Article
T1 Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study.
A1 Martinez-Cuadron, David
A1 Megias-Vericat, Juan E
A1 Serrano, Josefina
A1 Martinez-Sanchez, Pilar
A1 Rodriguez-Arboli, Eduardo
A1 Gil, Cristina
A1 Aguiar, Eliana
A1 Bergua, Juan
A1 Lopez-Lorenzo, Jose L
A1 Bernal, Teresa
A1 Espadana, Ana
A1 Colorado, Mercedes
A1 Rodriguez-Medina, Carlos
A1 Lopez-Pavia, Maria
A1 Tormo, Mar
A1 Algarra, Lorenzo
A1 Amigo, Maria-Luz
A1 Sayas, Maria J
A1 Labrador, Jorge
A1 Rodriguez-Gutierrez, Juan I
A1 Benavente, Celina
A1 Costilla-Barriga, Lissette
A1 Garcia-Boyero, Raimundo
A1 Lavilla-Rubira, Esperanza
A1 Vives, Susana
A1 Herrera, Pilar
A1 Garcia-Belmonte, Daniel
A1 Herraez, Maria Mar
A1 Vasconcelos Esteves, Graça
A1 Gomez-Roncero, Maria I
A1 Cabello, Ana
A1 Bautista, Guiomar
A1 Balerdi, Amaia
A1 Mariz, Jose
A1 Boluda, Blanca
A1 Sanz, Miguel A
A1 Montesinos, Pau
K1 Neoplasms, second primary
K1 Registries
K1 Remission induction
AB Secondary acute myeloid leukemia (sAML) comprises a heterogeneous group of patients and is associated with poor overall survival (OS). We analyze the characteristics, treatment patterns, and outcomes of adult patients with sAML in the Programa Español de Tratamientos en Hematología (PETHEMA) registry. Overall, 6211 (72.9%) were de novo and 2310 (27.1%) had sAML, divided into myelodysplastic syndrome AML (MDS-AML, 44%), MDS/myeloproliferative AML (MDS/MPN-AML, 10%), MPN-AML (11%), therapy-related AML (t-AML, 25%), and antecedent neoplasia without prior chemotherapy/radiotherapy (neo-AML, 9%). Compared with de novo, patients with sAML were older (median age, 69 years), had more Eastern Cooperative Oncology Group ≥2 (35%) or high-risk cytogenetics (40%), less FMS-like tyrosine kinase 3 internal tandem duplication (11%), and nucleophosmin 1 (NPM1) mutations (21%) and received less intensive chemotherapy regimens (38%) (all P, .001). Median OS was higher for de novo than sAML (10.9vs 5.6 months; P , .001) and shorter in sAML after hematologic disorder (MDS, MDS/MPN, or MPN) compared with t-AML and neo-AML (5.3 vs 6.1 vs 5.7 months, respectively; P 5 .04). After intensive chemotherapy, median OS was better among patients with de novo and neo-AML (17.2 and 14.6 months, respectively). No OS differences were observed after ypomethylatingagents according to type of AML. sAML was an independent adverse prognostic factor for OS. We confirmed high prevalence and adverse features of sAML and established its independent adverse prognostic value
PB American Society of Hematology
YR 2021
FD 2021-10-12
LK http://hdl.handle.net/10668/20247
UL http://hdl.handle.net/10668/20247
LA en
NO Martínez-Cuadrón D, Megías-Vericat JE, Serrano J, Martínez-Sánchez P, Rodríguez-Arbolí E, Gil C, et al. Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study. Blood Adv. 2022 Feb 22;6(4):1278-1295
NO This study was supported in part by the Jazz Pharmaceuticals and Cooperative Research Thematic Network (RTICC) grant RD12/0036/014 (ISCIII and ERDF).
DS RISalud
RD Apr 7, 2025